Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody - Institut Pasteur Access content directly
Journal Articles Nature Year : 2020

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto
  • Function : Author
Siro Bianchi
  • Function : Author
Stefano Jaconi
  • Function : Author
Katja Culap
  • Function : Author
Fabrizia Zatta
  • Function : Author
Anna de Marco
  • Function : Author
Alessia Peter
  • Function : Author
Barbara Guarino
  • Function : Author
Katja Fink
  • Function : Author
  • PersonId : 1029614
David Veesler
  • Function : Author
  • PersonId : 1022763
Davide Corti
  • Function : Author

Abstract

SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 20201,2. Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe multiple monoclonal antibodies targeting SARS-CoV-2 S identified from memory B cells of an individual who was infected with SARS-CoV in 2003. One antibody, named S309, potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 by engaging the S receptor-binding domain. Using cryo-electron microscopy and binding assays, we show that S309 recognizes a glycan-containing epitope that is conserved within the sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails including S309 along with other antibodies identified here further enhanced SARS-CoV-2 neutralization and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309- and S309-containing antibody cocktails for prophylaxis in individuals at high risk of exposure or as a post-exposure therapy to limit or treat severe disease.

Dates and versions

pasteur-02623374 , version 1 (26-05-2020)

Identifiers

Cite

Dora Pinto, Young-Jun Park, Martina Beltramello, Alexandra Walls, M. Alejandra Tortorici, et al.. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 2020, ⟨10.1038/s41586-020-2349-y⟩. ⟨pasteur-02623374⟩
60 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More